| abstract |
The present invention relates to the CGRP antagonists of the general formula in which A and R 1 to R 3 are defined as in claim 1, their tautomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, and the hydrates of the salts, in particular their physiologically acceptable salts with inorganic or organic acids, Medicaments containing these compounds, their use and processes for their preparation. |